Enrique Grande Pulido-rekin lankidetzan egindako argitalpenak (7)

2023

  1. Tailored immunotherapy approach with nivolumab with or without nivolumab plus ipilimumab as immunotherapeutic boost in patients with metastatic renal cell carcinoma (TITAN-RCC): a multicentre, single-arm, phase 2 trial

    The Lancet Oncology, Vol. 24, Núm. 11, pp. 1252-1265

2021

  1. Circulating levels of the interferon-γ-regulated chemokines cxcl10/cxcl11, il-6 and hgf predict outcome in metastatic renal cell carcinoma patients treated with antiangiogenic therapy

    Cancers, Vol. 13, Núm. 11

2018

  1. Experience with Sunitinib in metastatic renal cell carcinoma (mRCC) patients: pooled analysis from 3 Spanish observational prospective studies

    Expert Opinion on Drug Safety, Vol. 17, Núm. 6, pp. 573-579

2017

  1. HIF pathway and c-Myc as biomarkers for response to sunitinib in metastatic clear-cell renal cell carcinoma

    OncoTargets and Therapy, Vol. 10, pp. 4635-4643

  2. Recent advances in genitourinary tumors: A review focused on biology and systemic treatment

    Critical Reviews in Oncology/Hematology, Vol. 113, pp. 171-190

2016

  1. Expert Recommendations for First-Line Management of Metastatic Renal Cell Carcinoma in Special Subpopulations

    Targeted Oncology, Vol. 11, Núm. 2, pp. 129-141

2011

  1. Experience in the use of sunitinib given as a single agent in metastatic chemoresistant and castration-resistant prostate cancer patients

    Expert Opinion on Pharmacotherapy, Vol. 12, Núm. 16, pp. 2433-2439